SG11202000055PA - Antibodies that modulate a biological activity expressed by a cell - Google Patents

Antibodies that modulate a biological activity expressed by a cell

Info

Publication number
SG11202000055PA
SG11202000055PA SG11202000055PA SG11202000055PA SG11202000055PA SG 11202000055P A SG11202000055P A SG 11202000055PA SG 11202000055P A SG11202000055P A SG 11202000055PA SG 11202000055P A SG11202000055P A SG 11202000055PA SG 11202000055P A SG11202000055P A SG 11202000055PA
Authority
SG
Singapore
Prior art keywords
utrecht
yalelaan
international
cell
bind
Prior art date
Application number
SG11202000055PA
Other languages
English (en)
Inventor
Cecilia Anna Wilhelmina Geuijen
Rinse Klooster
Kruif Cornelis Adriaan De
Paulus Johannes Tacken
Mark Throsby
Ton Logtenberg
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of SG11202000055PA publication Critical patent/SG11202000055PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
SG11202000055PA 2017-07-06 2018-07-06 Antibodies that modulate a biological activity expressed by a cell SG11202000055PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17180070 2017-07-06
PCT/NL2018/050451 WO2019009728A1 (fr) 2017-07-06 2018-07-06 Anticorps qui modulent une activité biologique exprimée par une cellule

Publications (1)

Publication Number Publication Date
SG11202000055PA true SG11202000055PA (en) 2020-02-27

Family

ID=59295099

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000055PA SG11202000055PA (en) 2017-07-06 2018-07-06 Antibodies that modulate a biological activity expressed by a cell

Country Status (14)

Country Link
US (2) US11732043B2 (fr)
EP (1) EP3649156A1 (fr)
JP (1) JP2020525533A (fr)
KR (1) KR20200037250A (fr)
CN (2) CN111094350A (fr)
AU (1) AU2018297061B2 (fr)
BR (1) BR112020000228A2 (fr)
CA (1) CA3068933A1 (fr)
EA (1) EA202090005A1 (fr)
IL (1) IL271833A (fr)
PH (1) PH12020550010A1 (fr)
SG (1) SG11202000055PA (fr)
TW (1) TW201920275A (fr)
WO (1) WO2019009728A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117586403A (zh) 2016-10-11 2024-02-23 艾吉纳斯公司 抗lag-3抗体及其使用方法
EP3565841A1 (fr) 2017-01-06 2019-11-13 Crescendo Biologics Limited Anticorps à domaine unique dirigés contre pd1 (mort cellulaire programmée 1)
GB201802573D0 (en) * 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
CN112236456B (zh) * 2018-03-20 2023-12-22 上海药明生物技术有限公司 新型双特异性pd-1/lag-3抗体分子
EA202091871A1 (ru) * 2018-03-30 2021-06-22 Мерус Н.В. Поливалентное антитело
WO2020216348A1 (fr) * 2019-04-26 2020-10-29 Wuxi Biologics (Shanghai) Co., Ltd. Anticorps bispécifiques dirigés contre pd-1 et lag-3
BR112021022405A2 (pt) 2019-05-09 2022-04-19 Merus Nv Domínios variantes para multimerização de proteínas e separação das mesmas
CA3176564A1 (fr) 2020-05-27 2021-12-02 Agilent Technologies, Inc. Anticorps anti-lag-3 humains et leur utilisation en immunohistochimie (ihc)
CN112225813B (zh) * 2020-10-21 2021-12-21 北京智仁美博生物科技有限公司 针对破伤风毒素的抗体及其用途
EP4019633A1 (fr) * 2020-12-23 2022-06-29 Technische Universität München Connecteurs de cellule conditionnels
EP4314062A1 (fr) 2021-03-31 2024-02-07 Merus N.V. Nouveaux domaines de liaison à pd-1
CA3213682A1 (fr) 2021-03-31 2022-10-06 Simon Edward PLYTE Fractions de liaison multispecifiques comprenant de nouveaux domaines de liaison au pd-1
EP4314061A1 (fr) 2021-03-31 2024-02-07 Merus N.V. Nouveaux anticorps multispécifiques
US20240101718A1 (en) * 2022-09-28 2024-03-28 Incyte Corporation Anti-pd-1/lag-3 bispecific antibodies and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
ES2442615T5 (es) 2002-07-18 2023-03-16 Merus Nv Producción recombinante de mezclas de anticuerpos
WO2018157954A1 (fr) 2017-03-01 2018-09-07 Fluorchemie Gmbh Frankfurt Nouveau matériau, ainsi que sa fabrication pour une utilisation en tant que milieu accumulateur dans un système sensible d'accumulation d'énergie dans la plage des basses températures, des températures moyennes et des hautes températures
CA2970873C (fr) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Anticorps monoclonaux humains pour mort programmee 1 (mp-1) et procedes pour traiter le cancer en utilisant des anticorps anti-mp-1 seuls ou associes a d'autres immunotherapies
CA2721093A1 (fr) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Lieurs d'albumine de serum humain, et ses conjugues
EP2556747B1 (fr) 2008-06-27 2020-12-02 Merus N.V. Souris transgéniques produisant un anticorps
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US9181342B2 (en) 2008-09-12 2015-11-10 Isis Innovation Limited PD-1 specific antibodies and uses thereof
CA2736829C (fr) 2008-09-12 2018-02-27 Isis Innovation Limited Anticorps specifiques de pd-1 et leurs utilisations
CA2833636A1 (fr) 2011-04-20 2012-10-26 Amplimmune, Inc. Anticorps et autres molecules qui se lient a b7-h1 et a pd-1
ES2893855T3 (es) 2011-08-11 2022-02-10 Ono Pharmaceutical Co Agente terapéutico para enfermedades autoinmunes que comprende agonista de PD-1
NZ630551A (en) 2012-04-20 2017-11-24 Merus Nv Methods and means for the production of ig-like molecules
NZ630563A (en) 2012-09-27 2017-04-28 Merus Nv Bispecific igg antibodies as t cell engagers
ME03558B (fr) * 2014-03-14 2020-07-20 Novartis Ag Molécules d'anticorps anti-lag-3 et leurs utilisations
TWI693232B (zh) * 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
WO2016011069A1 (fr) 2014-07-15 2016-01-21 The Board Of Trustees Of The Leland Stanford Junior University Utilisations médicales d'agonistes de cd38 (anticorps)
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
KR20180019725A (ko) * 2015-06-23 2018-02-26 메모리얼 슬로안-케터링 캔서 센터 신규의 피디 1 면역 조절제
PT3328419T (pt) * 2015-07-30 2021-11-26 Macrogenics Inc Moléculas de ligação pd-1 e métodos de utilização
WO2017024515A1 (fr) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Nouveaux anticorps anti-pd-1
US11124569B2 (en) 2015-09-18 2021-09-21 Dana-Farber Cancer Institute, Inc. Methods of reducing liver PD-1-expressing CD8+ T cells using PD-1 Fc fusion proteins that bind Fc receptors
TWI756187B (zh) * 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
MX2018004988A (es) * 2015-10-23 2018-11-09 Merus Nv Moleculas de union que inhibe el crecimiento de cancer.
KR102317574B1 (ko) * 2015-11-18 2021-10-26 머크 샤프 앤드 돔 코포레이션 Pd1 및/또는 lag3 결합제
WO2018053405A1 (fr) 2016-09-19 2018-03-22 Celgene Corporation Procédés de traitement de troubles immunitaires à l'aide de protéines de liaison à pd-1
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
JP7305538B2 (ja) * 2016-09-23 2023-07-10 メルス ナムローゼ フェンノートシャップ 細胞によって発現される生物活性を調節する結合分子
EP3389702A4 (fr) 2017-02-22 2019-08-14 I-Mab Anticorps anti-lag-3 et leurs utilisations
DE202017102208U1 (de) 2017-03-03 2018-03-07 Sarah Yanik Zusammensetzung, insbesondere für die Behandlung von Huf- und Klauenerkrankungen bei Tieren, und deren Herstellung
TW201920657A (zh) * 2017-07-06 2019-06-01 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的抗體
EP3649154A1 (fr) * 2017-07-06 2020-05-13 Merus N.V. Molécules de liaison permettant de moduler l'activité biologique exprimée par une cellule
WO2020167122A1 (fr) * 2019-02-14 2020-08-20 Merus N.V. Production de compositions comprenant deux anticorps ou plus
EP4157354A1 (fr) 2020-05-27 2023-04-05 Dana-Farber Cancer Institute, Inc. Molécules bispécifiques pour moduler sélectivement des lymphocytes t

Also Published As

Publication number Publication date
PH12020550010A1 (en) 2020-10-12
BR112020000228A2 (pt) 2020-07-14
EP3649156A1 (fr) 2020-05-13
CA3068933A1 (fr) 2019-01-10
JP2020525533A (ja) 2020-08-27
AU2018297061A1 (en) 2020-01-30
KR20200037250A (ko) 2020-04-08
IL271833A (en) 2020-02-27
CN117964759A (zh) 2024-05-03
WO2019009728A1 (fr) 2019-01-10
WO2019009728A8 (fr) 2020-01-09
CN111094350A (zh) 2020-05-01
AU2018297061B2 (en) 2021-05-06
TW201920275A (zh) 2019-06-01
US20200216540A1 (en) 2020-07-09
US20230406932A1 (en) 2023-12-21
US11732043B2 (en) 2023-08-22
EA202090005A1 (ru) 2020-06-18

Similar Documents

Publication Publication Date Title
SG11202000055PA (en) Antibodies that modulate a biological activity expressed by a cell
SG11201809669RA (en) Use of glutamate modulating agents with immunotherapies to treat cancer
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201901700UA (en) Biaryl compounds useful as immunomodulators
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201805532XA (en) Multivalent and multispecific 41bb-binding fusion proteins
SG11201811184UA (en) Lag -3 binding members
SG11201908088RA (en) Antibodies against pd-l1
SG11201909949XA (en) Targeted immunotolerance
SG11201901899PA (en) Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
SG11201805870YA (en) Bispecific t cell engaging antibody constructs
SG11201806624XA (en) Deposition of molybdenum thin films using a molybdenum carbonyl precursor
SG11201910134SA (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201806267QA (en) Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose
SG11201906961UA (en) Polypeptide variants and uses thereof
SG11201803834UA (en) Methods for treating conditions associated with masp-2 dependent complement activation
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201810801QA (en) Brain delivery protein
SG11201901272WA (en) Mesenchymal cell-derived exosomes to treat neurological disorders